Bicycle Therapeutics plc (NASDAQ:BCYC) CTO Michael Skynner Sells 3,287 Shares of Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) CTO Michael Skynner sold 3,287 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total value of $46,313.83. Following the completion of the transaction, the chief technology officer now owns 124,658 shares of the company’s stock, valued at approximately $1,756,431.22. This represents a 2.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Bicycle Therapeutics Stock Up 1.7 %

Shares of NASDAQ BCYC opened at $15.14 on Wednesday. The stock’s 50 day moving average price is $19.09 and its two-hundred day moving average price is $21.82. Bicycle Therapeutics plc has a 52-week low of $12.17 and a 52-week high of $28.67. The stock has a market capitalization of $1.05 billion, a P/E ratio of -4.60 and a beta of 0.92.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.04. The business had revenue of $2.68 million for the quarter, compared to analyst estimates of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business’s revenue was down 50.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.26) EPS. On average, analysts anticipate that Bicycle Therapeutics plc will post -3.05 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of BCYC. Armistice Capital LLC grew its position in shares of Bicycle Therapeutics by 17.9% during the 2nd quarter. Armistice Capital LLC now owns 1,972,000 shares of the company’s stock valued at $39,913,000 after buying an additional 300,000 shares during the last quarter. Westfield Capital Management Co. LP boosted its stake in Bicycle Therapeutics by 21.5% in the third quarter. Westfield Capital Management Co. LP now owns 1,850,945 shares of the company’s stock valued at $41,887,000 after acquiring an additional 327,089 shares during the period. First Light Asset Management LLC grew its holdings in shares of Bicycle Therapeutics by 16.1% during the second quarter. First Light Asset Management LLC now owns 1,384,768 shares of the company’s stock valued at $28,028,000 after purchasing an additional 191,717 shares during the last quarter. Point72 Asset Management L.P. raised its position in shares of Bicycle Therapeutics by 1,438.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 899,799 shares of the company’s stock worth $20,362,000 after purchasing an additional 841,299 shares during the period. Finally, Avoro Capital Advisors LLC bought a new stake in shares of Bicycle Therapeutics in the 2nd quarter worth approximately $14,168,000. 86.15% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

BCYC has been the subject of several analyst reports. B. Riley decreased their target price on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Stephens began coverage on shares of Bicycle Therapeutics in a research report on Friday, November 8th. They issued an “equal weight” rating and a $25.00 price objective for the company. HC Wainwright dropped their target price on Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating on the stock in a research report on Monday, December 16th. Royal Bank of Canada reissued an “outperform” rating and issued a $35.00 price target on shares of Bicycle Therapeutics in a report on Friday, November 1st. Finally, JMP Securities dropped their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a report on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $35.25.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.